On Thursday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: Opko Health, Inc. (NYSE:OPK), Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), SOLAREDGE TECHNOLOGIES INC (NASDAQ:SEDG), Hanwha Q CELLS Co., Ltd. (NASDAQ:HQCL)

Opko Health, Inc. (NYSE:OPK), with shares gained 2.81%, closed at $14.27.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), with shares jumped 17.36%, settled at $6.76.

SOLAREDGE TECHNOLOGIES INC (NASDAQ:SEDG), with shares climbed 15%, and closed at $20.70.

Hanwha Q CELLS Co., Ltd. (NASDAQ:HQCL), surged 14.62%, and closed at $1.96.

Latest NEWS regarding these Stocks are depicted underneath:

Opko Health, Inc. (NYSE:OPK)

Opko Health, Inc. (OPK), declared recently that SciVac Ltd., an Israeli entity in which OPKO has a forty-five percent ownership interest, has reached an contract following which Levon Resources Ltd. (LVN.TO)(LVNVF)(LO9.F) will attain 100% of the issued and outstanding ordinary shares of SciVac by way of a court-approved plan of arrangement. Upon closing, Levon intends to change its name to SciVac Inc., and the current officers and directors of SciVac will be the officers and directors of New SciVac post-closing. The current owners of SciVac will own 68.4% of the outstanding shares of New SciVac post-closing, with OPKO owning about 30% of the outstanding shares.

New SciVac will retain CAD $27 million in cash following the transaction. All other assets and other liabilities of the current Levon business are being transferred to a newly formed corporation to be owned 100% by the current Levon shareholders.

OPKO Health, Inc., a biopharmaceutical and diagnostics corporation, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)

Conatus Pharmaceuticals Inc. (CNAT), declared top-line results from the corporation’s Phase 2 double-blind, placebo-controlled clinical trial of emricasan, a first-in-class, orally active pan-caspase protease inhibitor, in 38 patients with nonalcoholic fatty liver disease (NAFLD), counting the subset of NAFLD patients with nonalcoholic steatohepatitis (NASH). The trial met its primary endpoint, showing a statistically noteworthy(p<0.05) reduction in alanine amino transferase (ALT) in patients treated for 28 days with emricasan at 25 mg twice per day dosing contrast to patients in the placebo control group. Reductions from baseline in ALT at Day 28 of about 39% in the emricasan treatment arm and about 14% in the placebo arm were similar to results observed in previous trials. Elevated baseline levels of three key serum biomarkers — caspase-cleaved cytokeratin 18 (cCK18), full length cytokeratin 18, and caspase 3/7 — also showed statistically noteworthy reductions from baseline in emricasan-treated patients at Day 28. The baseline elevation in cCK18 confirmed that the underlying targets of emricasan’s mechanism, apoptosis and inflammation, which are believed to drive liver disease progression, were engaged in the NAFLD/NASH patients in this trial. A reduction from baseline in cCK18 at Day 28 of about 30% in the emricasan treatment arm and an raise from baseline of about 4% in the placebo arm were similar to results observed in previous trials. The reduction in serum cCK18 levels demonstrated that emricasan can effectively reduce inflammation and elevated levels of apoptosis in NAFLD/NASH patients. These results were consistent with data obtained from the corporation’s previous clinical trials in other liver disease patient populations.

Conatus Pharmaceuticals Inc., a biotechnology corporation, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products comprise Emricasan, an orally active pan-caspase protease inhibitor, which is in Phase 2 clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post liver transplant clearance of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease.

SOLAREDGE TECHNOLOGIES INC (NASDAQ:SEDG)

Nasdaq (NDAQ) declared that trading of SOLAREDGE TECHNOLOGIES INC (SEDG), commenced on The Nasdaq Stock Market on March 26, 2015.

“SolarEdge is dedicated to transforming the world by making clean energy affordable through its solutions,” said Nelson Griggs, Executive Vice President of Listing Services at Nasdaq. “We are happy to add another ground-breaking clean energy technology corporation to the Nasdaq family and we are excited to celebrate more milestones with SolarEdge in the future.”

SolarEdge Technologies, Inc. manufactures and supplies DC optimized inverter systems for solar PV installations. The corporation’s DC optimized inverter system comprises of power optimizers, inverters, and cloud-based monitoring software. Its products are used in a range of solar market segments, counting residential solar installations, and commercial and small utility-scale solar installations.

Hanwha Q CELLS Co., Ltd. (NASDAQ:HQCL)

Formerly on March 16, Hanwha Q CELLS Co., Ltd. (HQCL), declared that its US entity has signed a $20 million three-year Senior Secured Revolving Credit Facility with Wells Fargo Capital Finance. The credit line will be used for working capital and other general corporate purposes.

Jay SEO, chief financial officer of Hanwha Q CELLS said, “We are happy to have secured this credit line from Wells Fargo, one of the most well-respected US financial institutions and active financiers of renewable energy. Its confidence demonstrates the combined strength of our newly-merged companies (Hanwha SolarOne and Hanwha Q CELLS) to meet rigid credit standards, in addition to access funding outside of our traditional sources in China and South Korea.” Mr. SEO concluded, “The US is a key planned market for our corporation and we are particularly well-positioned to capture share with our diverse ‘tariff free’ manufacturing base outside of mainland China.”

Hanwha Q CELLS Investment Co., Ltd. manufactures solar cells and modules, solar system solutions, and power plants. The corporation is based in Cayman Islands. The corporation operates as a partner of Hanwha Solar Holdings Co., Ltd.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.